Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Shire Adds To HGT Unit With Lotus Acquisition; Gets Preclinical Rare Disease Treatment

This article was originally published in The Pink Sheet Daily

Executive Summary

Shire makes a bolt-on acquisition that will complement both its rare disease franchise and its regenerative medicines unit.

Advertisement

Related Content

FDA Breakthrough Designation Generates Big Meetings, Big Results, Scioderm Says
FDA Breakthrough Designation Generates Big Meetings, Big Results, Scioderm Says
Spurring Innovation While Economizing On R&D Spending Remains Industry-Wide Challenge
Biopharma Dealmaking Quarterly Statistics, Q1 2013
Few Exits, But Lots Of Cash: Third Rock Closes $516M Third Fund
A New CEO And Perhaps A New Era At Shire: An Interview With Flemming Ornskov
Lotus Tissue Repair Scores $26 Million in Series A Round
Advanced BioHealing To Bring Regeneration To Shire
Lilly To Buy Alnara And Its Non-Porcine Pancreatic Enzyme Replacement Therapy
Shire/TKT: The Price of Diversification

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS074869

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel